Omeros

Omeros Corporation to Announce Third Quarter 2019 Financial Results on November 12, 2019

Retrieved on: 
星期三, 十一月 6, 2019
Biotechnology, Pharmaceutical, Health, Omeros, Conference call, NASDAQ, Literature, Finance, Oral communication

Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its third quarter 2019 financial results for the period ended September 30, 2019, on Tuesday, November 12, 2019, after the market closes.

Key Points: 
  • Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its third quarter 2019 financial results for the period ended September 30, 2019, on Tuesday, November 12, 2019, after the market closes.
  • Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.
  • To access the live conference call via phone, please dial (844) 831-4029 from the United States and Canada or (920) 663-6278 internationally.
  • To access the live and subsequently archived webcast of the conference call, go to Omeros website at www.omeros.com and select Events under the Investors section of the website.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - OMER

Retrieved on: 
星期一, 十一月 4, 2019
Abraham Pomerantz, Pomerantz, Securities Class Action, Omeros, Literature

NEW YORK, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation (Omeros or the Company) (NASDAQ: OMER).

Key Points: 
  • NEW YORK, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation (Omeros or the Company) (NASDAQ: OMER).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • On November 4, 2019, Omeros issued a press release announcing the results of a prospective study of the Companys ophthalmic drug Omidria.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.

FDA Confirms Omeros’ Schedule for Rolling Review of the Company’s BLA for Narsoplimab in the Treatment of HSCT-TMA

Retrieved on: 
星期三, 九月 11, 2019
Biotechnology, FDA, Health, Pharmaceutical, Health, Food and Drug Administration, United States Public Health Service, Omeros, Breakthrough therapy, Literature, Articles

Under its rolling review process, FDA can review components of a marketing application as they are submitted rather than requiring all components to be received prior to initiating review, allowing faster review of the application.

Key Points: 
  • Under its rolling review process, FDA can review components of a marketing application as they are submitted rather than requiring all components to be received prior to initiating review, allowing faster review of the application.
  • The BLA for narsoplimab, because of the drugs breakthrough therapy designation from FDA for the treatment of HSCT-TMA, is also eligible for priority review, which shortens the standard FDA review cycle by four months.
  • Omeros referenced FDAs agreement with the companys proposed schedule for its rolling BLA during a webcast presentation given yesterday by Gregory A. Demopulos, M.D., Omeros chairman and chief executive officer, at the H.C. Wainwright 21st Annual Global Investment Conference.
  • Omeros has multiple Phase 3 and Phase 2 clinical-stage development programs focused on: complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; cognitive impairment; and addictive and compulsive disorders.

Omeros Corporation to Announce First Quarter 2019 Financial Results on May 9, 2019

Retrieved on: 
星期一, 五月 6, 2019
Health, Biotechnology, Optical, Omeros, Conference call, NASDAQ, Literature, Finance, Oral communication

Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter 2019 financial results for the period ended March 31, 2019, on Thursday, May 9, 2019, after the market closes.

Key Points: 
  • Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter 2019 financial results for the period ended March 31, 2019, on Thursday, May 9, 2019, after the market closes.
  • Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.
  • To access the live conference call via phone, please dial (844) 831-4029 from the United States and Canada or (920) 663-6278 internationally.
  • To access the live and subsequently archived webcast of the conference call, go to Omeros website at www.omeros.com and select Events under the Investors section of the website.